|
|
Article: Elan and UCB Announce Agreement to Co-Promote New Migraine Drug FROVA (TM); Product to Be Launched Q'2 2002.
- Article from:
- PR Newswire
- Article date:
- March 28, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland and SMYRNA, Ga. -- Elan Corporation, plc ("Elan") and UCB Pharma, Inc., the US affiliate of a Belgium R&D-based international pharmaceutical and chemical group ("UCB"), announced today that they have entered into an agreement to co-promote the new migraine drug FROVA (frovatriptan succinate) in the United States. Elan and UCB will launch FROVA in the second quarter of 2002.
Under the terms of the co-promotion agreement, UCB will co-promote FROVA with Elan to neurologists using their combined sales forces of 265 field personnel. UCB will also promote FROVA with its primary care sales force of approximately 475 field representatives. The ...